Page last updated: 2024-11-11

norgestomet

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norgestomet: synthetic 19-norprogesterone that synchronizes estrus in cattle without reducing fertility; affects pituitary gonadotropins & the menstrual cycle in humans; minor descriptor (79-86), on-line & INDEX MEDICUS search PREGNENEDIONES (79-86); RN given refers to (11beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9820838
CHEMBL ID2104744
SCHEMBL ID140382
MeSH IDM0263320

Synonyms (37)

Synonym
norgestomet
19-norpregn-4-ene-3,20-dione, 17-hydroxy-11-beta-methyl-, acetate
17-(acetyloxy)-11-beta-methyl-19-norpregn-4-ene-3,20-dione
17-alpha-acetoxy-11-beta-19-norpreg-4-ene-3,20-dione
sc 21009
norgestometum [inn-latin]
19-norpregn-4-ene-3,20-dione, 17-(acetyloxy)-11-methyl-, (11beta)-
einecs 246-611-8
11beta-methyl-3,20-dioxo-19-nor-4-pregnen-17-yl acetat
17-hydroxy-11beta-methyl-19-norpregn-4-ene-3,20-dione acetate
norgestomet (usan/inn)
25092-41-5
D05210
19-norpregn-4-ene-3,20-dione, 17-(acetyloxy)-11-methyl-, (11-beta)-
17-(acetyloxy)-11 beta-methyl-19-norpregn-4-ene-3,20-dione
sc-21009 ,
CHEMBL2104744
3l33ud42x4 ,
norgestomet [usan:inn:ban]
unii-3l33ud42x4
norgestometum
19-norpregn-4-ene-3,20-dione, 17-(acetyloxy)-11-methyl-, (11.beta.)-
norgestomet [mart.]
norgestomet [inn]
norgestomet [usan]
norgestomet [green book]
SCHEMBL140382
17alpha-acetyloxy-11beta-methyl-19-norprogesterone
DB11440
Q21098963
DTXSID901016491 ,
[(8r,9s,10r,11s,13s,14s,17r)-17-acetyl-11,13-dimethyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
dtxcid101474681
norgestometum (inn-latin)
norgestomet (mart.)
bdbm50587263
AKOS040744418

Research Excerpts

Overview

Norgestomet is a synthetic progesterone derivative applied in veterinary medicine to control estrus and ovulation in cattle.

ExcerptReferenceRelevance
"Norgestomet is a synthetic progesterone derivative applied in veterinary medicine to control estrus and ovulation in cattle. "( Synthesis of Norgestomet and its 17β-isomer and evaluation of their agonistic activities against progesterone receptor.
Akiyama, H; Demizu, Y; Hosoe, J; Ito, T; Kurohara, T; Misawa, T; Sakai, T; Shoda, T; Tsuji, G; Uchiyama, N; Yanase, Y; Yokoo, H, 2021
)
2.43

Effects

ExcerptReferenceRelevance
"Norgestomet has been widely used in the livestock industry to promote the synchronization of estrus in cattle and increase pregnancy rates."( Synthesis of Norgestomet and its 17β-isomer and evaluation of their agonistic activities against progesterone receptor.
Akiyama, H; Demizu, Y; Hosoe, J; Ito, T; Kurohara, T; Misawa, T; Sakai, T; Shoda, T; Tsuji, G; Uchiyama, N; Yanase, Y; Yokoo, H, 2021
)
1.71

Treatment

Norgestomet treatment had an immediate and a prolonged effect on ovarian activity in those females classified as having inactive ovaries at the start of the AI program. Treatment had no effect on serum progesterone concentrations of the pregnant heifers on d 21 after the initial AI.

ExcerptReferenceRelevance
"Norgestomet treatment increased (P < .05) the timed breeding pregnancy rates for both presynchronization anestrous and cyclic cows."( Norgestomet and gonadotropin-releasing hormone enhance corpus luteum function and fertility of postpartum suckled beef cows.
Cruz, LC; Kesler, DJ; Ott, RS; Troxel, TR, 1993
)
2.45
"Norgestomet treatment had no effect on serum progesterone concentrations of the pregnant heifers on d 21 after the initial AI."( Norgestomet implants synchronize estrus and enhance fertility in beef heifers subsequent to a timed artificial insemination.
Faulkner, DB; Favero, RJ; Kesler, DJ, 1993
)
2.45
"Norgestomet treatment had no effect (P > .25) on the calving rates from the initial timed AI or from the return estrus."( Effect of norgestomet treatment after insemination on the calving rate of postpartum suckled beef cows.
Faulkner, DB; Favero, RJ; Kesler, DJ; Nash, TG, 1995
)
1.41
"Norgestomet treatment had an immediate and a prolonged effect on ovarian activity in those females classified as having inactive ovaries at the start of the AI program."( Calving rates in a tropical beef herd after treatment with a synthetic progestagen, norgestomet, or a prostaglandin analogue, cloprostenol.
Frisch, JE; O'Neill, CJ, 1996
)
1.24
"Norgestomet treatment altered (P < .01) ovarian follicular characteristics at all ages."( Effect of age and pattern of gain on induction of puberty with a progestin in beef heifers.
Bellows, RA; Bellows, SE; Hall, JB; MacNeil, MD; Short, RE; Staigmiller, RB, 1997
)
1.02
"Norgestomet-prostaglandin-treated females were implanted with a SMB implant without the estradiol valerate/norgestomet injection at the time of implant insertion and received 25 mg prostaglandin F2alpha (PGF) i.m."( Comparison of three approaches for synchronization of ovulation for timed artificial insemination in Bos indicus-influenced cattle managed on the Texas gulf coast.
Amstalden, M; Stanko, RL; Williams, GL; Williams, SW, 2002
)
1.04
"Treatment with norgestomet implants on d 12 through 21 had no detrimental effects on established or subsequent pregnancy, synchronized the return estrus of nonpregnant cows, and was efficacious in establishing pregnancy early postpartum."( Effect of norgestomet treatment after insemination on the calving rate of postpartum suckled beef cows.
Faulkner, DB; Favero, RJ; Kesler, DJ; Nash, TG, 1995
)
1.03

Dosage Studied

Gonadorelin was abolished at any dosage in Exp. 05 (5 micrograms) among heifers that received norgestomet implants compared to control heifer.

ExcerptRelevanceReference
"Two experiments were conducted to determine whether dosage of estradiol valerate (EV) or day of estrous cycle when treatment was administered affected response to Syncro-Mate-B (SMB)."( Luteal function, estrous response, and pregnancy rate after treatment with Norgestomet and various dosages of estradiol valerate in suckled cows.
Burns, GL; Plyler, BB; Pratt, SL; Spitzer, JC, 1991
)
0.51
" The dosage of GnRH was 250 micrograms, and implants prolong the induced LH surge."( Gonadotropin-releasing hormone enhances the calving rate of beef females administered norgestomet and alfaprostol for estrus synchronization.
Cruz, LC; doValle, ER; Kesler, DJ, 1997
)
0.52
"05) among heifers that received norgestomet implants compared to control heifers but was not completely abolished at any dosage in Exp."( Norgestomet implants prevent pregnancy in beef heifers on pasture.
Alexander, B; Evans, RR; Faulkner, DB; Geary, TW; Guardia, R; Hanks, DR; Holcombe, D; Randel, RD; Reeves, JJ; Rutter, LM; Sasser, RG; Schafer, DW, 1997
)
2.02
"05) with increasing dosage of gonadorelin (up to 5 micrograms) in norgestomet-implanted bulls (36 mg)."( Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine.
Kesler, DJ; Peterson, CA; Steckler, TL; Summers, RN, 1999
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Progesterone receptorHomo sapiens (human)EC50 (µMol)0.00450.00010.40478.2000AID1832935
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1832934Agonist activity at PR in human T47D cells using p-nitrophenyl phosphate as substrate assessed as induction of alkaline phosphatase activity at 1 nM incubated for 72 hrs followed by substrate addition measured after 24 hrs by alkaline phosphatase assay re2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Synthesis of Norgestomet and its 17β-isomer and evaluation of their agonistic activities against progesterone receptor.
AID1832937Agonist activity at PR in human T47D cells using p-nitrophenyl phosphate as substrate assessed as fold increase in alkaline phosphatase activity at 25 nM incubated for 72 hrs followed by substrate addition measured after 24 hrs by alkaline phosphatase ass2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Synthesis of Norgestomet and its 17β-isomer and evaluation of their agonistic activities against progesterone receptor.
AID1832935Agonist activity at PR in human T47D cells using p-nitrophenyl phosphate as substrate assessed as induction of alkaline phosphatase activity incubated for 72 hrs followed by substrate addition measured after 24 hrs by alkaline phosphatase assay2021Bioorganic & medicinal chemistry, 11-01, Volume: 49Synthesis of Norgestomet and its 17β-isomer and evaluation of their agonistic activities against progesterone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (168)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (17.86)18.7374
1990's78 (46.43)18.2507
2000's43 (25.60)29.6817
2010's16 (9.52)24.3611
2020's1 (0.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.72 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index43.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (10.59%)5.53%
Reviews2 (1.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other150 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]